The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.
 
Nancy L. Bartlett
Consulting or Advisory Role - Acerta Pharma; ADC Therapeutics; BTG; Roche/Genentech; Seagen
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); Autolus (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Forty Seven (Inst); Immune Design (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Christopher A. Yasenchak
Stock and Other Ownership Interests - Karyopharm Therapeutics (I)
Honoraria - Seagen; Takeda
Consulting or Advisory Role - BeiGene
Speakers' Bureau - BeiGene
Research Funding - Seagen
 
Khaleel K. Ashraf
No Relationships to Disclose
 
William N. Harwin
Research Funding - Sarah Cannon Research Institute
 
James Michael Orcutt
No Relationships to Disclose
 
Philip Kuriakose
Stock and Other Ownership Interests - Apellis Pharmaceuticals; Aprea Therapeutics; CTI; Pfizer
Consulting or Advisory Role - Apellis Pharmaceuticals; Chiesi; CTI BioPharma Corp; Incyte; Kedrion Biopharma; Pfizer; Sanofi
Research Funding - Bayer (Inst); Merck (Inst); Pfizer (Inst); Shire (Inst)
 
Pier Luigi Zinzani
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Bristol-Myers Squibb; Celltrion; EUSA Pharma; Gilead Sciences; Incyte; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Novartis; Roche; Sandoz; Secura BIO; SERVIER; Takeda; TG Therapeutics
Speakers' Bureau - EUSA Pharma; MSD; Novartis
 
Adrija Mamidipalli
No Relationships to Disclose
 
Keenan Fenton
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Travel, Accommodations, Expenses - Seagen
 
Consuelo Glenn
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Bantam Pharmaceutical; Celgene (Inst); Debiopharm Group; Genentech (Inst); Karyopharm Therapeutics; Kite/Gilead; kymera; MorphoSys (Inst); Ryvu Therapeutics; Selvita; TG Therapeutics
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)